Second Genome, Pfizer research microbiome; Deal or no deal – Merck/Agenus, Endo/Somar, Parion/Gilead begin, end relationships; Lightstone initiates new VC fund; Kite Pharma raises private cash; and GlobeImmune, Mapi-Pharma, Scynexis, Aldeyra, Ambrx move toward IPOs.
Second Genome, Pfizer search microbiome for obesity targets






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
